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ABSTRACT   
Background. Contemporary survival studies in hypertrophic cardiomyopathy (HCM) have 
shown that the prognosis for most individuals with the disease is much better than described 
previously, but it remains unclear whether HCM conveys an excess mortality when compared 
to the general population.  
Methods. We conducted a retrospective, multicentre longitudinal cohort study of adult HCM 
patients from 7 European centers. To compare survival to the general population standardized 
mortality ratios (SMR) were calculated using data from Eurostat stratified by study period, 
country, sex and age, using a composite endpoint (all-cause mortality, sudden cardiac death 
(SCD) equivalent, and heart transplantation).   
Results. The study population consisted of 4893 patients (mean age 49.2 ± 16.4 years; 64% 
male). After a median follow up of 6.1 years (IQR 3.0-9.8), 796 (16.3%) patients reached the 
composite endpoint. HCM had an excess mortality compared to the general population (SMR 
2.23 (95% Confidence Interval (CI):1.66-2.94)). Females were older at presentation, more 
symptomatic at baseline (NYHA III/IV: 17.1% vs 7.5%) and more likely to have left 
ventricular outflow tract obstruction and atrial fibrillation. Female patients had a greater excess 
mortality than males (SMR 2.87 (95% CI: 2.57-3.19) vs 1.92 (95% CI: 1.76-2.11); p<0.001). 
Excess mortality in females was present throughout the age spectrum while mortality in male 
patients after the age of 65 years was similar to the normal population. Female sex was 
independently associated with a worse prognosis in the multivariable model for the primary 
composite endpoint (HR 1.19, 95% CI:1.06-1.30;p=0.007) and HF death or transplantation 
(HR 1.44, 95% CI:1.25-1.59;p<0.001), but not SCD or equivalent. 
Conclusions. HCM is associated with a significant excess mortality throughout the life course. 
Women have a worse prognosis that is at least partly due to an excess HF mortality. 
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INTRODUCTION 
Hypertrophic cardiomyopathy (HCM) is a common genetic heart disease with a prevalence of 
at least 1 in 500 (1). The diagnosis is based on the presence of haemodynamically unjustified 
significant left ventricular (LV) hypertrophy (≥15mm on echocardiography or cardiac 
magnetic resonance), even though a positive family history lowers the diagnostic threshold (2). 
Approximately 50% of patients carry a mutation in a gene encoding a sarcomeric protein that 
is inherited as an autosomal dominant trait with incomplete prevalence (3). MYH7 and 
MYBPC3, that encode components of the thick-filament, are the two most commonly 
responsible genes with a combined relative prevalence of 60-70%. Almost all remaining 
genotype-positive cases are due to mutations in 6 other sarcomeric genes (TNNT2, TPM1, 
MYL2, MYL3, TNNI3 and ACTC1) (4–7). Phenotypic heterogeneity is well established in HCM 
with significant phenotype variation even within the same family, probably due to genetic and 
possibly acquired modifiers (6). Various attempts to establish genotype-phenotype correlations 
have been unsuccessful, but emerging evidence suggests a more aggressive phenotype in 
MYH7 HCM, with a younger age at presentation and a higher heart failure (HF) mortality (7). 
Research into novel disease-causing genes is ongoing, but novel genes account only for a 
modest proportion of ‘gene-negative’ patients. In fact, a polygenic substrate is probably 
responsible for the remaining ~50% of HCM patients in whom a mutation in the main 8 
sarcomeric genes is not found (8). It has however been quite well established that HCM patients 
with sarcomeric mutations have an overall worse prognosis compared to those whithout (6).  
In HCM, LV hypertrophy is asymmetric in most cases, but can also be concentric or 
predominately apical (9). The associated mitral valve abnormalities (elongated leaflets and 
anteriorised antero-lateral papillary muscle (10)), along with the hypertrophy of the basal 
septum, lead to systolic anterior movement of the mitral valve leaflets, a dynamic LV outflow 
tract (LVOT) obstruction and, in most cases, a posteriorly directed mitral regurgitation (11). A 
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significant LVOT obstruction can be documented in around 30% of patients in resting 
conditions, and up to 70% on exercise echocardiography (12). It is responsible for a reduced 
exercise tolerance in most patients, but is also associated with an overall worse prognosis due 
to HF and sudden cardiac death (SCD) (13, 14). Long-term data support the use of surgical 
myectomy to improve HF symptoms and probably prognosis (15), while alcohol septal ablation 
should be reserved for patients who are not surgical candidates since it improves symptoms, 
but some concerns over long-term risk of ventricular arrhythmias persists (16). 
LVOT obstruction however is not the only pathophysiological mechanism leading to HF in 
HCM. Diastolic dysfunction is a hallmark of HCM and has a complex pathogenesis that 
includes a combination of abnormal LV relaxation, abnormal intracellular calcium homeostasis 
and reduced chamber compliance (17). In some cases with a ‘restrictive pathophysiology’, no 
significant LVOT obstruction is present and LV ejection fraction is preserved, and a severe 
diastolic function is the prominent HF mechanism (18).  
A subgroup of 3-5% patients go on to develop ‘burn-out’ HCM, with progressive LV 
remodelling, systolic dysfunction, extensive fibrosis (19) and wall thinning (20, 21). Prognosis 
in this subgroup is grim with a high mortality due mainly to refractory HF, but also SCD (20, 
21). The pathogenesis of ‘burn-out’ HCM remains unclear, but based on the presence of large 
areas of transmural scar it has been suggested that microvascular ischemia has a prominent role 
(19–21). The only factors that have been associated with this disease progression are a family 
history of ‘burn-out’ HCM (21) and a higher  ̶  albeit modest  ̶  prevalence multiple sarcomeric 
mutations (13%) (22).        
Atrial fibrillation has a prevalence of around 20% in HCM, plays a prominent 
pathophysiological role and has historically been considered a turning point in the natural 
history of the disease (23–25). This is due to the fact that it is often associated with the 
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occurrence (or worsening) of HF as the loss of atrial contribution to LV filling is poorly 
tolerated in these patients. It is also associated with a significant thromboembolic risk 
mandating anticoagulation (26, 27). However, a recent report suggests that the combination of 
an aggressive rhythm-control strategy and a low threshold for anticoagulation have 
significantly reduced its impact on disease-related morbidity and mortality (28).     
Early HCM cohort studies reported a high mortality due to SCD and HF but were limited by a 
significant selection bias (29). Due to increased physician awareness, improved imaging 
techniques and systematic family screening, the number of mildly affected patients in 
contemporary cohorts has increased significantly and it is now well established that HCM has 
an extremely heterogeneous natural history (29–34). This ranges from young patients who 
experience SCD or develop refractory HF, to patients who are diagnosed incidentaly, remain 
completely asymptomatic throughout their lifetime and die of an unrelated cause. 
Contemporary management, that includes use of implantable defibrillators (ICD) (35, 36), 
improved SCD risk stratification (37), surgical myectomy (15) and early anticoagulation for 
atrial arrhythmias, has undoubtedly improved outcomes compared to the early cohorts, but a 
significant number of patients still experience HCM-related morbidity and mortality. In fact, 
whether HCM actually conveys an excess mortality compared to the general population 
remains to be established since the issue has only been investigated in small, selected subgroups 
(15, 32, 33, 38).    
The presence of sex differences in HCM has been known for some time (39), with a male 
predominance and important baseline clinical differences, but it has only recently been 
suggested that female sex is associated with a worse survival (40, 41). The pathophysiology 
underlying this outcome difference remains to be investigated.  
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AIMS 
1) Too compare the survival of patients with HCM in a large multicentre European cohort 
with that observed in the general population using contemporaneous country, age and 
sex-stratified European mortality data.  
2) To investigate the presence of sex-related differences in baseline clinical profile, 
survival and mode of death. 
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METHODS 
Study design and overview  
The study was carried out using data from a retrospective, multicentre longitudinal cohort  ̶  the 
Hypertrophic Cardiomyopathy Outcome Investigators (www.HCMRisk.org)(37). The study 
conforms to the principles of the Helsinki declaration. The investigators from each centre 
guarantee the integrity of data from their institution.  
Study population and participating centres 
The study cohort consisted of all consecutive HCM patients with valid follow up who were 
evaluated between 1980 and 2013 at seven European centres: (i) The Heart Hospital, London, 
UK; (ii) A Coruña University Hospital, A Coruña, Spain; (iii) Unit of Inherited Cardiovascular 
diseases, 1st Department of Cardiology, University of Athens, Greece; (iv) Institute of 
Cardiology, Alma Mater University of Bologna, Italy; (v) University Hospital Virgen de la 
Arrixaca, Murcia, Spain; (vi) Monaldi Hospital, Università della Campania “Luigi Vanvitelli”, 
Italy; and (vii) Hospital Universitario Puerta del Hierro, Madrid, Spain. Data from the 
Hypertrophic Cardiomyopathy Outcome Investigators cohort have been reported in other 
studies (26, 37, 42–45). Only adult patients (≥16 years of age) were included. HCM was 
defined as a maximum LV wall thickness ≥15mm unexplained solely by loading conditions (2) 
or in accordance with published criteria for the diagnosis of disease in relatives of patients with 
unequivocal disease (46). Patients with known inherited metabolic diseases or syndromic 
causes of HCM were excluded.  
Patient assessment and data collection 
Patients were reviewed every 6–12 months or earlier if there was a change in symptoms. At 
presentation, all patients underwent clinical assessment, pedigree analysis, physical 
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examination, resting and ambulatory electrocardiography (ECG), and transthoracic 
echocardiography. Each centre collected data independently using the same methodology. 
Definition of baseline variables 
Family history of sudden cardiac death (SCD) was defined as a history of sudden cardiac death 
in one or more first-degree relatives under 40 years of age or SCD in a first degree relative with 
confirmed HCM at any age (post- or antemortem diagnosis)(14). Maximum left ventricular 
(LV) wall thickness was defined as the greatest thickness in the anterior septum, posterior 
septum, lateral wall, and posterior wall of the LV, measured at the level of the mitral valve, 
papillary muscles, and apex in the parasternal short-axis plane using 2-D echocardiography 
(47). LV ejection fraction was calculated using the Teichholz method (48). The left atrial (LA) 
diameter was determined by M-Mode or 2D echocardiography in the parasternal long axis 
plane (49). The maximum LV outflow gradient was determined at rest and with Valsalva 
provocation (irrespective of concurrent medical treatment) using pulsed and continuous wave 
Doppler from the apical three- and five-chamber views. Peak outflow tract gradients were 
determined using the modified Bernoulli equation (gradient = 4V2, where V is the peak aortic 
outflow velocity on continuous wave Doppler) (14). Non-sustained ventricular tachycardia was 
defined as ≥3 consecutive ventricular beats at a rate of ≥120 bpm and <30 s in duration on 
Holter monitoring (minimum duration 24 hours) at or prior to first evaluation (50). Syncope 
was defined as a history of unexplained syncope at or prior to first evaluation (49). 
Outcomes 
A composite endpoint was used for the main survival analysis, consisting of all-cause mortality, 
SCD or equivalent (aborted SCD, appropriate implantable cardioverter defibrillator (ICD) 
shock therapy) and heart transplantation. The cause of death was ascertained by experienced 
cardiologists at each centre using hospital and primary health care records, death certificates, 
10 
 
post-mortem reports, and interviews with witnesses (relatives and physicians). SCD was 
defined as witnessed sudden death with or without documented ventricular fibrillation or death 
within one hour of new symptoms or nocturnal deaths with no antecedent history of worsening 
symptoms (47). Successfully resuscitation from ventricular fibrillation or ventricular 
tachycardia during follow-up and appropriate ICD shock therapy were considered equivalent 
to SCD (13, 50–54), but anti-tachycardia pacing was not. Data on aborted SCD or sustained 
ventricular tachycardia (at a rate of ≥120 beats per minute lasting >30 seconds) preceding the 
presentation were collected, but not included in the study end-point. Other cardiovascular (CV) 
death included stroke, heart failure deaths and procedure-related deaths. Heart transplantation 
was considered equivalent to death from heart failure. The follow-up time for each patient was 
taken to be the time from diagnosis to the primary composite endpoint, end of study period or 
last follow-up date. Patients who were alive at the end of study period or who were lost to 
follow-up were treated as censored. 
Ethical approval 
Patients at A Coruña University Hospital (Spain), 1st Department of Cardiology, University of 
Athens (Greece), University Hospital Virgen de la Arrixaca (Spain), and Monaldi Hospital 
(Italy) provided written informed consent. Data collection at The Heart Hospital (UK) and 
Hospital Universitario Puerta de Hierro (Spain) was approved by the local ethics committees. 
The ethics committee at the Institute of Cardiology at the University of Bologna (Italy) were 
informed, but approval was not required under local research governance arrangements. 
Statistical analysis 
Statistical analyses were carried out with IBM SPSS Statistics for Windows, version 24.0 (IBM 
Corp., Armonk, N.Y., USA) and STATA version 12. For descriptive statistics, variables are 
expressed as mean ± standard deviation (SD), median (interquartile range, IQR) or counts and 
11 
 
percentages as appropriate. The follow-up time for each patient was calculated from the date 
of first evaluation at participating centres to the date of the relevant endpoint or to the date of 
their most recent evaluation. For comparisons between groups, the chi-square test was used for 
categorical variables and Student’s t-test or Mann–Whitney for continuous variables, as 
appropriate. 
Standardized mortality ratios (SMR) were calculated as actual deaths/expected deaths ratio 
using data from Eurostat (55) extracted on 18/08/17. Eurostat is the statistical office of the 
European Union that supplies the public and European institutions with data and statistics with 
the objective of defining, implementing and analyzing European Union policies. Expected 
mortality was based on the mortality rates from the appropriate period for each centre and was 
stratified by country, sex and age at the end of follow up. Patient age at the end of follow up 
was used for the calculation of expected mortality based on yearly mortality rates by age in the 
general population. For the calculation of expected deaths, each patient contributed person-
years to the different age categories he/she was assigned to from presentation and throughout 
follow up (e.g. a patient who presented aged 20 and died at 32 contributed 5 years follow up to 
the 20-25 age group, 5 to the 25-30 age group, and 2 to the 30-35 age group).  SMRs were 
calculated using the main combined study endpoint; 95% confidence intervals and comparisons 
were estimated by Poisson regression. Indirectly adjusted mortality rates were obtained by 
multiplying the crude rate of the standard population by the SMRs  and 95% confidence 
intervals were calculated as previously described (56).  
Cox proportional hazards modelling 
Univariable and multivariable Cox regression models were fitted for each endpoint and tested 
for non-linearity of continuous predictors by inclusion of quadratic terms. The correct 
functional forms of continuous predictor variables were also assessed by visual analysis of 
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cumulative plots of Martingale residuals. Candidate predictor variables were selected based 
previous description of an association with the study endpoint or pathophysiological 
plausibility. Sample size guidelines for Cox regression suggest that at least 10 events per 
candidate variable are required to obtain unbiased parameter estimates (coefficients and HRs) 
with correct standard errors (57). The proportional hazards assumption was verified using 
Schoenfeld residuals (58). To determine the degree of bias due to missing data, the 
characteristics of patients with missing information were compared with those with complete 
information. Logistic regression was used to identify the predictors of missingness. Data were 
assumed to be missing at random, and values for the missing predictors were imputed using 
multiple imputation techniques based on chained equations (59). All predictors of missingness 
were included in the multiple imputation model, together with the outcome, potential predictors 
and the estimate of the cumulative hazard function (60). The number of imputations was based 
on the percentage of missingness and the estimates were combined using Rubin’s rules (61).  
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RESULTS 
The study population consisted of 4893 patients that were followed for a total of 33,717.3 
person-years. Table 1 reports the baseline characteristics of the study population and Figure 1 
shows the distribution by age at presentation. 
Outcomes 
After a median follow up of 6.1 years (IQR 3.0-9.8), 796 patients (16.3%) reached the 
composite primary endpoint. Of these, 263 patients (5.4%) met the SCD or equivalent endpoint 
(137 (2.8%) SCD, 96 (2%) appropriate ICD shocks and 30 (0.6%) aborted SCD); 200 (4.1%) 
met the heart failure (HF) death or equivalent endpoint (123 (2.5%) actual HF death, 77 (1.6%) 
cardiac transplant); 103 (2.1%) died of other CV causes; 210 (4.3%) died from non-CV causes 
and 20 (0.4%) of unknown causes. During follow up 390 (8%) patients underwent septal 
reduction treatment [282 (5.8%) septal myectomy, 93 (1.9%) alcohol septal ablation and 15 
(0.3%) both procedures].  
Overall, patients with HCM had an excess mortality compared to the general population (SMR 
2.23 (95% CI: 1.66-2.94). Figure 2A shows the calculated SMR by age, with values >1 
indicating excess mortality compared to the general population; Figure 2B reports the 
indirectly adjusted mortality rates by age in the study population. The main cause of death in 
younger patients was SCD (or equivalent), but this accounted for progressively smaller 
percentage of total deaths with advancing age, while HF death or cardiac transplantation 
accounted for a similar proportion of events throughout the age spectrum. Other CV and non-
CV causes increased progressively after the age of 45 years (Figure 3). Figure 4 shows the 
event rates according to age at presentation. The rate of SCD varied with age, while the rate of 
HF death or transplantation, other CV and non-CV death increased after the age of 65.  
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Sex differences 
Male and female patients had a different baseline clinical profile (Table 2). Females were older 
at presentation, more symptomatic (NYHA III/IV: 17.1% vs 7.5%) and more likely to have a 
family history of SCD and a history of syncope. LV wall thickness and systolic function were 
similar in men and women, but females were more likely to have LVOT obstruction. Women 
were also more likely to have or develop atrial fibrillation (AF) during the study (Table 3) and 
have a history of hypertension. 
Female patients had a greater excess mortality than males (SMR 2.87 (95% CI: 2.57-3.19) vs 
1.92 (CI 1.76-2.11); p<0.001). Excess mortality in females was present throughout the age 
spectrum while mortality in male patients after the age of 65 years was similar to the normal 
population (Figure 5). Figure 6 reports the event rates by sex and age at presentation. 
More than 10 events per predictor were present for each of the multivariable models. Female 
sex was independently associated with a worse prognosis in the multivariable model for the 
composite study endpoint (HR 1.19, 95% CI: 1.06-1.30; p=0.007. Table 4) and HF death or 
transplantation (HR 1.44, 95% CI: 1.25-1.59; p<0.001. Table 5), but not SCD or equivalent 
(Table 6). In the multivariable model for the primary composite endpoint septal myectomy had 
a protective effect, but no interaction between sex and septal myectomy was present (HR 1.06, 
95% CI 0.53-2.14; p= 0.862). 
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DISCUSSION 
In a large, international multicentre cohort we show that adult patients with HCM have an 
excess mortality compared to the general population. Female patients have a greater excess 
mortality than men, and this is at least partly due to heart failure. 
Outcomes in HCM 
Previous studies have described HCM-related mortality in specific age groups (30–32), and a 
very recent report from the SHaRe registry (62) described the outcomes in a large multicentre 
HCM population in greater detail, but this is the first and largest study to compare survival in 
adult patients of all ages with contemporaneous national survival data from European countries. 
Our findings are consistent with previous studies showing that SCD is the predominant cause 
of death in younger adults, whereas HF deaths occurs throughout the life course. The rate of 
SCD is in line with previous reports and our data confirm the role of known important risk 
factors (47, 49, 51, 52). Overall, we confirmed that mortality is lower than reported in historical 
cohorts (29) and this is probably due to a significant selection bias. However, our data show 
that – even in the modern era – a diagnosis of HCM confers an excess mortality compared to 
the normal population.  
Most previous studies comparing survival in HCM with the general population focused on 
small subgroups of HCM patients (15, 32, 33, 38) and cannot be used to compared our findings. 
The only comparable data from the SHaRe registry (62), found that HCM patients treated in 
the US had a worse survival than the general population only in the younger (age 20-29) and 
older age groups (age 50-69). No survival difference compared to the general population was 
found when analysing the small subgroup (370 patients) with ‘non-familial HCM’ (defined as 
having negative genetic testing and no family history of HCM). The authors carried out an 
elegant analysis of lifetime disease burden in relation to genotype in mildly smaller cohort than 
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the present one, but the survival comparison with the general population was rudimentary. The 
incident Kaplan-Meier derived mortality over a 10-year period in the HCM cohort was simply 
compared to age-adjusted mortality in the overall US population. The analysis did not adjust 
for factors that significantly impact mortality such as sex, geographic location and study period, 
was only carried out in the subgroup of US patients (n=2029) and only up to the age of 69. 
These differences explain the fact that in a larger cohort and adjusting for more confounders, 
we documented an excess mortality throught the age spectrum. 
Sex differences in HCM 
A male predominance around 60% is a constant finding in large HCM cohorts (39, 41, 62–64) 
and significant sex-related differences in clinical profile at presentation have been known for 
some time. In line with our own observations, female HCM patients have been previously 
found to be older at presentation, more symptomatic and with a greater degree of LV outflow 
tract obstruction (39–41). Regarding outcome, recent reports in Chinese and North American 
populations have reported higher all-cause mortality in female patients (40, 41), in contrast to 
previous studies that had shown an excess HF and stroke mortality in women, but no difference 
in overall survival (39). In this study, we show that the excess mortality compared to the general 
population is greater in women than in men, and that this excess persists into the later decades 
of life in women in contrast to men over the age of 65 who have a similar mortality to the 
general population. With respect to the mode of death, SCD predominates in younger men 
whereas HF is the major cardiovascular cause of death in older women. 
Comparing our findings to the only other large study that specifically investigated sex 
differences in HCM some significant study design differences should be noted. The Mayo 
Clinic data (40) originate from a single referral centre, where a third of patients underwent 
septal reduction therapy (compared to 8% in our cohort). The study endpoint used was all-
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cause mortality and did not including SCD and HF death equivalents, thereby only partially 
capturing the HCM-related events throughout the long study period (1975-2012) during which 
treatment has improved significantly. Finally, cause of death was not reported. Our study 
confirms these findings, clarifying that sex-related differences in outcome are part of the 
disease natural history and not a difference in response to treatment. Importantly, our data also 
clarifies that the worse prognosis in female patients is at least partially due to a greater HF 
mortality, but unfortunately based only on the baseline phenotypic variables, our data does not 
allow us to establish the exact pathophysiology of this HF mortality. The available literature 
does not provide a possible explanation as no significant sex imbalance has been recorded in 
the available series of HCM patients with ‘burn-out’ progression and LV systolic dysfunction 
(18, 21, 22) or those with advanced HF with a preserved EF (18). 
The explanation for these sex differences in phenotype and outcome in HCM is not 
straightforward. The available evidence has started to explain why sex differences exist, but 
does not help us understand the different phenotype and the worse outcome in female patients. 
The male predominance and younger age of males at presentation could actually reflect a 
greater and earlier penetrance in males, as suggested in some small series of patients with 
sarcomeric mutations (65–68), however in larger series of patients with a clinical diagnosis of 
HCM, female sex has been associated with a higher prevalence of sarcomeric mutations on 
genetic testing (62, 69, 70). Murine models also suggest an earlier phenotypic expression in 
males (71–73), and phenotype (consisting of LV hypertrophy, function and fibrosis) appears 
to be the result of a complex interaction between sex, sex hormones, genotype (specific 
sarcomeric mutation, but also other genes such as androgen receptors) and hypertrophic stimuli 
(71–77). Mouse studies also suggest a different electrophysiological phenotype according to 
sex, but this does not help explain our findings since male mice have been found to be more 
predisposed to ventricular arrhythmias (71, 78), and the observed survival difference in patients 
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does not seem to be related to SD in both our data or previously published cohorts (39, 41). It 
is interesting to note however, that while in the general population the risk of atrial fibrillation 
is higher in males (79), the opposite appears to be true in HCM (45), and this could be related 
to higher LV filling pressures (E/e’) (40). Female sex is not however associated with a greater 
thrombo-embolic risk in HCM (26).  
In the broader context of HF of any aethiology, limited data is available regarding sex 
differences, but some large datasets have shown a worse survival in male patients (80). This 
has been attributed to the greater prevalence of LV systolic dysfunction in males, while females 
have been found to be older and more frequently have a preserved ejection fraction (81).  
Non-biological factors may also contribute to sex differences in HCM outcome, since women 
have been shown to have a reduced awareness of cardiovascular risk (82), a longer delay in 
seeking medical attention in acute coronary syndromes (83, 84) and have less access to 
screening programs (85, 86).  
 
  
19 
 
CONCLUSIONS 
HCM is associated with a significant excess mortality throughout the course of life. Women 
have a worse prognosis that is at least partly due to an excess HF mortality.  
In spite of the undoubted success of modern treatments for HCM, the implications of our 
findings are that further research into the causes of this excess mortality is required. Areas of 
interest include better risk stratification for both sudden and HF-related death as well as 
systematic exploration of therapies with the potential to attenuate or prevent adverse ventricular 
remodelling.  
   
LIMITATIONS 
Due to the historic nature of a considerable part of the study cohort, baseline cardiac MRI data 
were not collected in this dataset. Information on genotype was not collected in the present 
dataset and this leaves a number of unanswered questions that will require dedicated studies to 
investigate the relationship between genotype, sex and outcomes in HCM.  
A degree of survivor bias cannot be excluded in the present study, since it is possible that some 
patients died prior to evaluation in a referral centre or clinical diagnosis. Finally, all the 
participating centres are longstanding HCM referral units and a degree of referral bias is 
possibly present.    
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TABLES 
Table 1: Baseline characteristics of the study population (n=4893) 
 
HCM: hypertrophic cardiomyopathy; VF: ventricular fibrillation; VT: ventricular 
tachycardia; ICD: implantable cardioverter defibrillator; LV: left ventricle; LVOT: left 
ventricular outflow tract obstruction. 
 
 
 
  
Age at presentation (yrs) 49.2 ± 16.4 
Male sex 3126 (63.9%) 
Country:                                                                           Greece 
Spain 
Italy 
UK 
566 (11.6%) 
1497 (30.6%) 
733 (15%) 
2097 (42.9%) 
Family history of sudden death 1127/4752 (23.7%) 
Previous VF/sustained VT 134 (2.7%) 
NYHA class                                                                               I 
II 
III/IV 
2560 (54.6%) 
1613 (34.4%) 
514 (11%) 
Unexplained syncope 725/4846 (15%) 
Non-sustained VT on Holter  924/4204 (22%) 
ICD 816 (16.7%) 
Previous atrial fibrillation 653 (13.3%) 
Hypertension 1446/4783 (30.2%) 
Maximum LV wall thickness (mm) 19 (IQR 16-22) 
LV end-diastolic diameter (mm) 44.8 ± 6.5 
LV Ejection fraction ≤50% 396/4428 (8.9%) 
Maximum LVOT gradient (mmHg) 9 (IQR 4-50) 
LVOT gradient >50 mmHg 1087/4238 (25.6%) 
Left atrial diameter (mm) 44.1 ± 7.8 
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Table 2: Characteristics of the study population according to sex. 
HCM: hypertrophic cardiomyopathy; VF: ventricular fibrillation; VT: ventricular 
tachycardia; ICD: implantable cardioverter defibrillator; LV: left ventricle; LVOT: left 
ventricular outflow tract obstruction; AF: atrial fibrillation. 
 
  
 
Females 
(n=1767) 
Males  
(n=3126) P- value 
Age at presentation (yrs) 52.9 ± 17.2 47.1 ± 15.6 <0.001 
Follow up duration (yrs) 5.8 (IQR 2.8-9.5) 6.3 (IQR 3.1-9.9) 0.003 
Family history of sudden death 467/1709 
(27.3%) 
660/3043 
(21.7%) 
<0.001 
Previous VF/sustained VT 40 (2.3%) 94 (3%) 0.126 
NYHA class                                     I 
II 
  III/IV 
695 (41.2%) 
703 (41.7%) 
288 (17.1%) 
1865 (62.1%) 
910 (30.3) 
226 (7.5%) 
<0.001 
Unexplained syncope 289/1746 
(16.6%) 
436/3100 
(14.1%) 
0.020 
Non-sustained VT on Holter 296/1496 
(19.8%) 
628/2708 
(23.2%) 
0.011 
ICD 281 (15.9%) 535 (17.1%) 0.275 
Hypertension 616/1732 
(35.6%) 
830/3051 
(27.2%) 
<0.001 
Maximum LV wall thickness (mm) 18 (IQR 16-22) 19 (IQR 16-22) 0.003 
LV end-diastolic diameter (mm) 42.5 ± 6.2 46.1 ± 6.3 <0.001 
LV ejection fraction (%)  66 ± 12 65 ± 12 <0.001 
LV Ejection fraction ≤50% 8.3% 9.3% 0.251 
Maximum LVOT gradient (mmHg) 10 (IQR 4-64) 8 (IQR 4-44) <0.001 
LVOT gradient >50 mmHg 463/1545 (30%) 624/2693 
(23.2%) 
<0.001 
Left atrial diameter (mm) 43 ± 7.6 44.8 ± 7.9 <0.001 
AF at baseline or during follow up 591 (33.4%) 939 (30%) 0.014 
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Table 3. Events during follow up according to sex 
ICD: implantable cardioverter defibrillator; CV: cardiovascular. 
 
  
 
Females 
(n=1767) 
Males  
(n=3126) P- value 
Septal myectomy 118 (6.7%) 179 (5.7%) 0.180 
Alcohol septal ablation 47 (2.7%) 61 (2%) 0.105 
Sudden cardiac death (SCD) 36 (2.0%) 101 (3.2%) na 
Aborted SCD 10 (0.6%) 20 (0.6%) na 
Appropriate ICD shock 25 (1.4%) 71 (2.3%) na 
Heart failure death 70 (4.0%) 53 (1.7%) na 
Heart transplantation 36 (2.0%) 41 (1.3%) na 
Other CV death 51 (2.9%) 52 (1.7%) na 
Non-CV death 96 (5.4%) 114 (3.6%) na 
Unknown cause of death 11 (0.6%) 9 (0.3%) na 
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Table 4: Univariable and multivariable predictors of the primary composite endpoint.  
 
PRIMARY COMPOSITE ENDPOINT  
(all-cause mortality, transplantation, aborted SCD, appropriate ICD shock) 
 Univariable analysis Multivariable analysis 
Predictor HR 95% CI P-value HR 95% CI P-value 
Age at presentation (10 yrs) 1.39 1.32-1.45 <0.001 1.34 1.27-1.42 <0.001 
Female sex 1.28 1.17-1.37 <0.001 1.19 1.06-1.30 0.007 
Previous VF/VT 4.26 3.29-5.5 <0.001 3.82 2.93-4.99 <0.001 
NYHA                                      II 
III/IV 
1.43 
3.51 
1.21-1.68 
2.92-4.22 
<0.001 
 
1.11 
2.14 
0.93-1.31 
1.74-2.63 
<0.001 
Syncope 1.4 1.17-1.67 <0.001 1.23 1.03-1.48 0.025 
EF ≤50% 3.29 2.73-3.95 <0.001 2.11 1.73-2.57 <0.001 
MWT (5mm) 
[MWT (5mm)]2 
1.99 
0.94 
1.35-2.94 
0.88-0.98 
0.001 
0.003 
1.30 
0.98 
0.87-1.94 
0.94-1.03 
0.201 
0.435 
LA diameter (5mm) 1.34 1.29-1.39 <0.001 1.22 1.17-1.28 <0.001 
LVOT max (25mmHg increase)  1.06 1.01-1.11 0.011 1.02 0.97-1.07 0.520 
AF 1.56 1.36-1.8 <0.001 1.24 1.10-1.36 0.001 
NSVT on Holter 1.75 1.49-2.06 <0.001 1.29 1.08-1.54 0.005 
Family history of SD 1.12 0.96-1.31 0.157 1.30 1.10-1.54 0.002 
Stroke  1.67 1.35-2.07 <0.001 1.24 0.99-1.56 0.059 
Hypertension 1.21 1.03-1.41 0.018 1.28 1.15-1.39 <0.001 
Septal myectomy 0.63 0.45-0.89 0.009 0.56 0.39-0.80 0.002 
ASA 0.78 0.47-1.27 0.312 0.67 0.97-1.07 0.520 
Previous VF/VT: previous aborted sudden cardiac death or sustained ventricular tachycardia; 
EF: left ventricular (LV) ejection fraction; MWT: LV maximum wall thickness (for 5mm 
increase); LA diameter: left atrial diameter (for 5mm increase); LVOT max: maximum LV 
outflow tract gradient (for 25mmHg increase); AF: atrial fibrillation at baseline or during 
follow up; NSVT: non-sustained ventricular tachycardia; SD: sudden death; ASA: alcohol 
septal ablation.   
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Table 5: Univariable and multivariable predictors of heart failure endpoint.   
 
HEART FAILURE DEATH OR TRANSPLANTATION 
 Univariable analysis Multivariable analysis 
Predictor HR 95% CI P-value HR 95% CI P-value 
Age at presentation (10yrs) 1.31 1.20-1.44 <0.001 1.09 0.98-1.21 0.133 
Female sex 1.53 1.38-1.65 <0.001 1.44 1.25-1.59 <0.001 
Previous VF/VT 3.3 1.88-5.79 <0.001 2.58 1.41-4.71 0.002 
NYHA                                         II 
III/IV 
1.8 
9.16 
1.24-2.61 
6.46-13.01 
<0.001 1.46 
4.71 
0.99-2.16 
3.15-7.05 
<0.001 
EF ≤50% 7.48 5.52-10.13 <0.001 4.13 2.95-5.79 <0.001 
MWT (5mm) 0.95 0.83-1.08 0.429 0.96 0.83-1.11 0.592 
LA diameter (5mm) 
[LA diameter (5mm)]2 
3.46 
0.96 
1.79-6.70 
0.93-0.99 
<0.001 
0.015 
3.13 
0.96 
1.58-6.21 
0.93-0.99 
0.001 
0.012 
LVOTmax (25mmHg increase) 
[LVOTmax (25mmHg increase)]2 
0.83 
1.03 
0.67-1.02 
1.00-1.06 
0.077 
0.044 
0.77 
1.04 
0.62-0.96 
1.01-1.08 
0.023 
0.020 
AF 2.71 2.02-3.63 <0.001 1.08 0.77-1.52 0.656 
NSVT on Holter 1.81 1.32-2.49 <0.001 1.18 0.80-1.72 0.400 
Hypertension 1.02 0.65-1.29 0.898 1.47 1.24-1.63 0.001 
Septal myectomy 0.78 0.41-1.48 0.451 0.52 0.26-1.05 0.069 
ASA 1.2 0.53-2.71 0.655 1.08 0.47-2.51 0.851 
Previous VF/VT: previous aborted sudden cardiac death or sustained ventricular tachycardia; 
EF: left ventricular (LV) ejection fraction; MWT: LV maximum wall thickness (for 5mm 
increase); LA diameter: left atrial diameter (for 5mm increase); LVOT max: maximum LV 
outflow tract gradient (for 25mmHg increase); AF: atrial fibrillation at baseline or during 
follow up; NSVT: non-sustained ventricular tachycardia; SD: sudden death; ASA: alcohol 
septal ablation.   
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 Table 6: Univariable and multivariable predictors of sudden death endpoint.                                                                                                                                                                                                                                       
 
Previous VF/VT: previous aborted sudden cardiac death or sustained ventricular tachycardia; 
EF: left ventricular (LV) ejection fraction; MWT: LV maximum wall thickness (for 5mm 
increase); LA diameter: left atrial diameter (for 5mm increase); LVOT max: maximum LV 
outflow tract gradient (for 25mmHg increase); AF: atrial fibrillation at baseline or during 
follow up; NSVT: non-sustained ventricular tachycardia; SD: sudden death; ASA: alcohol 
septal ablation.   
 
  
SUDDEN DEATH, ABORTED SCD OR APPROPRIATE ICD SHOCK 
 Univariable analysis Multivariable analysis 
Predictor HR 95% CI P-value HR 95% CI P-value 
Age at presentation (10yrs) 0.89 0.83-0.97 0.005 0.89 0.82-0.98 0.016 
Female sex 0.57 0.12-0.91 0.010 0.80 0.40-1.10 0.207 
Previous VF/VT 10.74 7.84-14.69 <0.001 6.21 4.50-8.86 <0.001 
NYHA                                    II 
III/IV 
0.96 
1.02 
0.74-1.25 
0.66-1.56 
0.946 0.87 
0.92 
0.66-1.16 
0.58-1.46 
0.466 
 
EF ≤50% 2.33 1.63-3.32 <0.001 1.80 1.25-2.61 0.002 
MWT (5mm) 
[MWT (5mm)]2 
3.06 
0.91 
1.56-6.02 
0.85-0.98 
0.001 
0.013 
2.30 
0.93 
1.16-4.56 
0.87-1.00 
0.018 
0.060 
LA diameter (5mm) 1.21 1.13-1.30 <0.001 1.16 1.06-1.26 0.001 
LVOTmax (25mmHg increase) 1.01 0.93-1.10 0.797 1.05 0.96-1.16 0.289 
AF 1.14 0.89-1.46 0.315 0.83 0.62-1.10 0.188 
NSVT on Holter 2.62 2.01-3.4 <0.001 2.15 1.62-2.84 <0.001 
Family history of SD 1.77 1.37-2.27 <0.001 1.59 1.22-2.07 <0.001 
Syncope 2.16 1.64-2.84 <0.001 1.74 1.31-2.32 <0.001 
Septal myectomy 0.63 0.34-1.15 0.131 0.57 0.30-1.07 0.081 
ASA 0.44 0.14-1.36 0.153 0.52 0.16-1.63 0.260 
37 
 
FIGURES 
 
 
 
Figure 1: Distribution of study cohort by age at presentation. 
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Figure 2: Standardised mortality ratios (SMR) in the study population reported by age (A; 
values >1 indicate an excess mortality compared to the general population), and indirectly 
adjusted mortality rates by age in the study population (B). HCM: hypertrophic 
cardiomyopathy. Age group 16-20 SMR clipped upper CI limit = 43.36. Age group >80 
adjusted mortality clipped upper CI limit 19.2%. 
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Figure 3: Cause of death in the study population by age group; CV: cardiovascular. 
 
 
 
 
 
 
 
Figure 4: Events rates in the study population according to age at presentation. SCD: sudden 
cardiac death; HF: heart failure; CV: cardiovascular. Rate of non-CV death in patients aged 
>80: 6.2%/yr. 
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Figure 5: Standardised mortality ratios (SMR) in the study population by age and sex (values 
>1 indicate an excess mortality compared to the general population). Females aged 16-20: 
clipped upper CI limit = 215.12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 
 
 
Figure 6: Events rates in the study population by sex, according to age at presentation. CV: 
cardiovascular. 
 
 
 
